We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ATECTURA BREEZHALER (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
ATECTURA BREEZHALER
Date registered
Evaluation commenced
Decision date
Approval time
194 working days (255)
Active ingredients
indacaterol acetate; mometasone furoate
Registration type
EOI
Indication
New Combination
ATECTURA BREEZHALER (microgram powder for inhalation in hard capsule with inhaler) is indicated as a once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older where use of a combination of long-acting beta2-agonist and inhaled corticosteroid is appropriate:
- patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting beta2-agonists or
- patients not adequately controlled with long-acting beta2-agonists and low dose of inhaled corticosteroids and 'as needed' inhaled short-acting beta2-agonists.